NTLA Key Statistics, Chart & Performance
The current stock price of NTLA is 9.55 USD. In the past month the price increased by 0.63%. In the past year, price decreased by -25.97%.
NTLA Latest News, Press Relases and Analysis
NTLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.86B | ||
| AMGN | AMGEN INC | 14.51 | 170.90B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.69 | 113.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 78.49B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 809.08 | 54.51B | ||
| INSM | INSMED INC | N/A | 41.64B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.3 | 25.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 21.04B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.24B | ||
| INCY | INCYTE CORP | 14.97 | 18.87B |
Related stock screener links
About NTLA
Company Profile
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 403 full-time employees. The company went IPO on 2016-05-06. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
Company Info
INTELLIA THERAPEUTICS INC
40 Erie St Ste 130
Cambridge MASSACHUSETTS 02139 US
CEO: John M. Leonard
Employees: 403
Phone: 18572856200
INTELLIA THERAPEUTICS INC / NTLA FAQ
What does INTELLIA THERAPEUTICS INC do?
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 403 full-time employees. The company went IPO on 2016-05-06. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
What is the current price of NTLA stock?
The current stock price of NTLA is 9.55 USD. The price increased by 1.92% in the last trading session.
What is the dividend status of INTELLIA THERAPEUTICS INC?
NTLA does not pay a dividend.
How is the ChartMill rating for INTELLIA THERAPEUTICS INC?
NTLA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists NTLA stock?
NTLA stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for INTELLIA THERAPEUTICS INC?
The Revenue of INTELLIA THERAPEUTICS INC (NTLA) is expected to grow by 7.96% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
NTLA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NTLA. When comparing the yearly performance of all stocks, NTLA is a bad performer in the overall market: 86.23% of all stocks are doing better.
NTLA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NTLA. No worries on liquidiy or solvency for NTLA as it has an excellent financial health rating, but there are worries on the profitability.
NTLA Financial Highlights
Over the last trailing twelve months NTLA reported a non-GAAP Earnings per Share(EPS) of -4.27. The EPS increased by 21.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.18% | ||
| ROE | -59.57% | ||
| Debt/Equity | 0 |
NTLA Forecast & Estimates
31 analysts have analysed NTLA and the average price target is 22.12 USD. This implies a price increase of 131.67% is expected in the next year compared to the current price of 9.55.
For the next year, analysts expect an EPS growth of 23.01% and a revenue growth 7.96% for NTLA